Intein-mediated expression and purification of an analog of glucagonlike peptide-1 in escherichia coli

Protein and Peptide Letters

Volumn 17, Issue 10, 2010, Pages 1245-1250

  Ma, Chen ^a   Gao, Mingming ^a   Liu, Wenchao ^a   Zhu, Jing ^a   Tian, Hong ^a   Gao, Xiangdong ^a   Yao, Wenbing ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Chitin beads; Expression and purification; Glucagon like peptide 1; Incretin; Intein; Self cleavage

Indexed keywords

DRUG DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; INTEIN;

AMINO ACID SEQUENCE; ANIMAL; ARTICLE; ESCHERICHIA COLI; GENETICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ISOLATION AND PURIFICATION; METABOLISM; MOLECULAR GENETICS; MOUSE; NUCLEOTIDE SEQUENCE; POLYACRYLAMIDE GEL ELECTROPHORESIS;

AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ESCHERICHIA COLI; GLUCAGON-LIKE PEPTIDE 1; INTEINS; MICE; MOLECULAR SEQUENCE DATA;

ESCHERICHIA COLI;

EID: 77958507775     PISSN: 09298665     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986610792231582     Document Type: Article

References (17)

1. Nauck, M.A.; Heimesaat, M.M.; Ørskov, C.; Holst, J.J.; Ebert, R.; Creutzfeldt, W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory poly-peptide in patients with type-2 diabetes mellitus. J. Clin. Invest., 1993, 91, 301-307.
2. Meier, J.J.; Gethmann, A.; Nauck, M.A.; Gotze, O.; Schnmitz, F.; Deacon, C.F.; Gallwitz, B.; Schmidt, W.E.; Holst, J.J. The gluca-gon-like peptide-1 metabolite GLP-1-(9-36) amide reduces post-prandial glycemia independently of gastric emptying and insulin secretion in humans. Am. J. Physiol. Endocrinol. Metab., 2006,290, E1118-E1123.
3. Penfornis, A.; Borot, S.; Raccah, D. Therapeutic approach of 2 diabetes mellitus with GLP-1 based therapies. Diabetes. Metab., 2008, 34, S78-S90.
4. Gaal, L.F.V.; Gutkin, S.W.; Nauck, M.A. Exploiting the antidia-betic properties of incretins to treat type 2 diabetes mellitus: gluca-gon-like peptide 1 receptor agonist or insulin for patient with in-adequate glycemic control? Eur. J. Endocrinol., 2008, 158, 773-784.
5. Holst, J.J.; Deacon, C.F. Inhibition of the Activity of Dipeptidyl-Peptidase as a Treatment for Type 2 Diabetes. Diabetes, 1998, 47(11), 1663-1670.
6. Knudsen, L.B.; Nielsen, P.F.; Huusfeldt, P.O.; Johansen,N.L.;Madsen, K.;Pedersen,F.Z.; Thøgersen, H.; Wilken, M.; Agersø,H.Potent Derivatives of Glucagon-like Peptide-1 with PropertiesSuitable for Once Daily Administration. J. Med. Chem., 2000,43(9), 1664-1669.
7. Deacon, C.F.; Knudsen, L.B.; Madsen, K.; Wiberg, F.C.; Jacobsen, O.; Holst, J.J. Dipeptidyl peptidase IV resistant analogues of gluca-gon-like peptide-1 which have extended metabolic stability and improved biological activity. Diabetologia, 1998, 41, 271-278.
8. Banki, M.R.; Wood, D.W. Intein and affinity resin substitutes for protein purification and scale up. Microbial Cell Factories, 2005,4, 32.
9. Perler, F.B.; Davis, E.O.; Dean, G.E.; Gimble, F.S.; Jack, W.E.;Neff, N.; Noren, C.J.; Thorner, J.; Belfort, M. Protein splicing ele-ments: inteins and exteins-a definition of terms and recommended nomenclature. Nucleic Acids Res., 1994, 22(7), 1125-1127.
10. Sun, Z.S.; Chen, J.Y.; Yao, H.W.; Liu, L.L.; Wang, J.; Zhang, J.;Liu, J.N. Use of Ssp dnaB derived mini-intein as a fusion partner for production of recombinant human brain natriuretic peptide inEscherichia coli. Protein. Expres. Purif., 2005, 43, 26-32.
11. Esipov, R.S.; Stepanenko, V.N.; Chupova, L.A.; Boyarskikh, U.A.; Filipenko, M.L.; Miroshnikov, A.I. Production of recombinant hu-man epidermal groeth factor using Ssp dnaB mini-intein system. Protein. Expres. Purif., 2008, 61, 1-6.
12. Wu, W.; Wood, D.W.; Belfort, G.; Derbyshire, V.; Belfort, M. Intein-mediated purification of cytotoxic endonuclease I-Tevby in-sertional inactivation and pH-controllable splicing. Nucleic AcidsRes., 2002, 30(22), 4864-4871.
13. Zhang, Z.Z.; Yang, S.S.; Dou, H.; Mao, J.F.; Li, K.S. Expression,purification, and C-terminal amidation of recombinant human glu-cagon-like peptide-1. Protein. Expres. Purif., 2004, 36, 292-299.
14. Yin, X.P.; Wei, D.Z.; Yi, L.; Tao, X.Y.; Ma, Y.S. Expression andpurification of exendin-4, a GLP-1 receptor agonist, in Escherichiacoli. Protein. Expres. Purif., 2005, 41, 259-265.
15. Mathys, S.; Evans, T.C.; Chute, I.C.; Wu, H.; Chong, S.R.; Benner,J.; Liu, X.Q.; Xu, M.Q. Characterization of a self-splicing mini-intein and its conversion into autocatalytic N- and C-terminalcleavage elements: facile production of protein building blocks forprotein ligation. Gene, 1999, 231, 1-13.
16. Esipov, R.S.; Stepanenko, V.N.; Gurevich, A.I.; Chupova, L.A.;Miroshnikov, A.I. Production and Purification of Recombinant Human Glucagon Overexpressed as Intein Fusion Protein in Es-cherichia coli. Protein. Peptide. Lett., 2006, 13, 343-347.
17. Che, N.Y.; Wang, L.L.; Gao, Y.; An, C.C. Soluble expression andone-step purification of a neurotoxin Huwentoxin-I in Escherichia coli. Protein. Expres. Purif., 2009, 65, 154-159.